Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
OCGN Stock Chart & Stats
$2.10
-$0.04(-4.99%)
At close: 4:00 PM EST
$2.10
-$0.04(-4.99%)
Day’s Range― - ―
52-Week Range$0.57 - $2.73
Previous CloseN/A
Volume1.89M
Average Volume (3M)8.91M
Market Cap
$688.58M
Enterprise Value$703.16M
Total Cash (Recent Filing)$18.57M
Total Debt (Recent Filing)$33.14M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 01, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding327,897,300
10 Day Avg. Volume15,709,927
30 Day Avg. Volume8,914,308
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue159.34
Enterprise Value/Gross Profit159.34
Enterprise Value/Ebitda-11.62
Forecast
1Y Price Target
$11.17Price Target Upside431.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$2.01M
Bulls Say, Bears Say
Bulls Say
Mechanism Of Action And Safety ProfileOCU410's modifier approach targeting a master gene regulator, combined with a reported favorable safety profile and no drug-related serious adverse events, could position the therapy as a durable, one-time alternative to frequent treatments.
Pipeline Breadth And Market OpportunityMultiple clinical-stage gene therapy programs addressing both rare retinal disorders and more common indications expand the number of potential milestones and increase the addressable patient market.
Pivotal Clinical ReadoutsSuccessful pivotal readouts for OCU400 in retinitis pigmentosa and for OCU410ST in Stargardt disease could support regulatory filings and act as major catalysts by validating clinical benefit across both mutation-specific and broad patient cohorts.
Bears Say
Clinical Data UncertaintyCurrent evidence is primarily from small, early-stage studies, creating uncertainty about whether positive signals will hold in larger, more definitive trials.
Financing And Dilution RiskA history of dilutive financings and limited cash resources that may necessitate additional capital raises creates dilution risk and could weigh on shareholder returns.
Investor Sentiment Toward Gene Therapy ClassPersistent investor skepticism toward gene therapies in this class could limit valuation upside and exert selling pressure despite encouraging clinical signals.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.57 and its highest was $2.73 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $688.58M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is May 01, 2026 which is in 38 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Mar 04, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.059 by -$0.001.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 327,897,300 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.059. Following the earnings report the stock price went up 5.376%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (431.90% Upside)
$11.17 (431.90% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
254.16%
12-Months-Change
Fundamentals
Return on Equity
-2626.38%
Trailing 12-Months
Asset Growth
-46.86%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
OCGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$11.17
▲(431.90% Upside)
Technical Analysis
Sinovac Biotech
―
XOMA Royalty Corporation
―
ADC Therapeutics
―
Monte Rosa Therapeutics
―
AbSci
―
Ownership Overview
2.52% Insiders
5.48% Mutual Funds
1.15% Other Institutional Investors
85.19% Public Companies and Individual Investors